$1.13
5.83% yesterday
Nasdaq, Jun 13, 10:18 pm CET
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Ocugen Inc Stock price

$1.13
+0.43 60.85% 1M
+0.27 31.79% 6M
+0.33 40.37% YTD
-0.39 25.66% 1Y
+0.86 318.52% 5Y
-417.67 99.73% 10Y
-703.87 99.84% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.07 5.83%
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Key metrics

Market capitalization $330.00m
Enterprise Value $319.87m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 57.74
P/S ratio (TTM) P/S ratio 59.57
P/B ratio (TTM) P/B ratio 20.73
Revenue growth (TTM) Revenue growth -21.42%
Revenue (TTM) Revenue $5.54m
EBIT (operating result TTM) EBIT $-69.26m
Free Cash Flow (TTM) Free Cash Flow $-51.95m
Cash position $37.80m
EPS (TTM) EPS $-0.25
P/E forward negative
P/S forward 130.94
EV/Sales forward 126.92
Short interest 23.83%
Show more

Is Ocugen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Ocugen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

Buy
100%

Financial data from Ocugen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5.54 5.54
21% 21%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 33 33
10% 10%
598%
- Research and Development Expense 42 42
13% 13%
752%
-67 -67
12% 12%
-1,201%
- Depreciation and Amortization 2.70 2.70
280% 280%
49%
EBIT (Operating Income) EBIT -69 -69
15% 15%
-1,250%
Net Profit -69 -69
19% 19%
-1,253%

In millions USD.

Don't miss a Thing! We will send you all news about Ocugen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocugen Inc Stock News

Neutral
GlobeNewsWire
3 days ago
MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO International Convention at the Boston Convention & Exhibition Center from June 16-19, 2025.
Neutral
GlobeNewsWire
9 days ago
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights t...
Neutral
GlobeNewsWire
18 days ago
MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) has granted Rare Pediatric Disease Designation (RPDD) for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt dis...
More Ocugen Inc News

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Head office United States
CEO Shankar Musunuri
Employees 95
Founded 2013
Website ocugen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today